Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by l‐tryptophan or 5‐methoxy‐N,N‐dimethyltryptamine in rats treated with a monoamine oxidase inhibitor
British Journal of Pharmacology December 1, 1971 DOI: 10.1111/j.1476-5381.1971.tb07222.x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | Chlorpromazine L-tryptophan monoamine oxidase inhibitor 5-methoxy-N N-dimethyltryptamine p-chlorophenylalanine |
| Topics | Serotonin 5-MeO-DMT DMT |
| Keywords | Chlorpromazine Monoamine oxidase inhibitor Monoamine neurotransmitter Antagonism Tryptophan Pharmacology Endocrinology Receptor Biochemistry Enzyme Amino acid |
| Citations | 179 |
| Key findings | Chlorpromazine inhibits hyperactivity and hyperpyrexia caused by L-tryptophan or 5-MeODMT after monoamine oxidase inhibition, likely by receptor competition or physiological antagonism. |
Abstract
1. The hyperactivity and hyperpyrexia produced by L-tryptophan in rats treated with a monoamine oxidase inhibitor was inhibited by chlorpromazine.2. Chlorpromazine did not inhibit the increased rate of synthesis of brain 5-hydroxytryptamine (5-HT) produced by tryptophan loading.3. Hyperactivity and hyperpyrexia were also produced by 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) in rats. Pretreatment with a monoamine oxidase inhibitor potentiated the hyperactivity response. Pretreatment of rats with p-chlorophenylalanine did not inhibit hyperactivity produced by 5-MeODMT.4. Chlorpromazine inhibits hyperactivity caused by tryptophan or 5-MeODMT after monoamine oxidase inhibition either by competition with 5-HT or 5-MeODMT, respectively, at receptor sites or by physiological antagonism.